Metabolite for diagnosis of cerebral apoplexy
Metabolomics screened out stroke-related biomarkers C14.0, C15.0, C20.0, and C18.3N6, and developed detection kits and calculation models to solve the accuracy of stroke diagnosis and early detection problems. Improves the patient's life and quality of life.
Patent Information
- Application Number
- CN202411164657.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-12
AI Technical Summary
The existing stroke diagnosis methods have problems such as accuracy and difficulty in early detection, which leads to insufficient treatment opportunities for patients and affects their life and quality of life.
Through metabolomics studies, biomarkers C14.0, C15.0, C20.0, and C18.3N6 related to stroke were screened out, and detection kits and calculation models were developed to evaluate the levels of these metabolites. Determine whether the subject has or is susceptible to stroke.
It realizes the early accurate diagnosis of stroke, improves the patient's life and quality of life, and provides the possibility of early intervention and treatment.
Smart Images

Figure CN118937530A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine and relates to metabolites used for diagnosing stroke. Background Art
[0002] Stroke, also known as cerebrovascular accident, is a central nervous system disease caused by sudden rupture or blockage of brain blood vessels, resulting in damage to brain tissue. It has the characteristics of high morbidity, high mortality, and high disability rate (Grysiewicz RA, et al. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors [J]. Neurol Clin, 2008, 26 (4): 871-895.). A systematic analysis of the Global Burden of Disease Study shows that stroke is the second leading cause of death worldwide, accounting for 11.6% of the total number of deaths; it is also the third leading cause of disability (Feigin VL, et al. World Stroke Organization (WSO): global stroke fact sheet 2022 [J]. Int J Stroke, 2022, 17 (1): 18-29). Stroke seriously threatens human life safety and quality of life, and brings huge economic and social burdens. Stroke includes ischemic stroke (IS) and hemorrhagic stroke (CH), of which IS has a higher incidence, accounting for 60% to 80% of the total number of strokes (Liu LP, et al. Chinese stroke association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischemic cerebrovascular diseases [J]. Stroke Vasc Neurol, 2020, 5 (2): 159-176.). Therefore, it is of great significance to study the pathophysiological process of IS and establish a complete IS prevention, diagnosis, treatment and prognosis system.
[0003] Metabolomics is an emerging omics technology and an important part of "system biology". The main research objects of metabolomics are small molecular compounds with a mass less than 1000 in body fluids, cells, and tissues of biological organisms. The main analysis platforms include high-resolution, high-sensitivity, and high-throughput modern instrumental analysis such as chromatography-mass spectrometry and nuclear magnetic resonance technology. It reveals the changes in metabolic pathways in the body by qualitatively or quantitatively studying the changes in the types, quantities, and contents of disturbed metabolites (endogenous metabolites) in the body. Metabolomics is at the terminal of transcription, gene and protein expression, and can directly and accurately reflect the pathological and physiological state of the organism. It is widely used in disease diagnosis, drug development, nutrition, toxicology, sports medicine and other fields, especially to provide reliable theoretical basis and means for clinical disease diagnosis. Studying metabolites with significant differences in blood and finding diagnostic markers are of great significance for the rapid and accurate diagnosis of stroke. Summary of the invention
[0004] In order to evaluate the correlation between metabolites and stroke, the present invention collects samples of healthy controls and stroke patients, comprehensively analyzes the metabolomics of the samples, screens metabolites with significant differences in content between the two groups, and further analyzes the diagnostic efficacy of the differential metabolites, thereby discovering biomarkers suitable for the diagnosis and treatment of stroke.
[0005] Specifically, the present invention provides the following technical solutions:
[0006] The present invention provides the use of a reagent for detecting a biomarker in a sample in the preparation of a product for diagnosing stroke, wherein the biomarker is selected from one or more of C14.0, C15.0, C20.0, and C18.3N6.
[0007] The present invention provides a kit, which comprises a reagent for detecting metabolites in a sample; and instructions for using the kit to evaluate whether a subject suffers from or is susceptible to stroke; the metabolites are selected from one or more of the following: C14.0, C15.0, C20.0, C18.3N6.
[0008] The present invention provides the use of metabolites in constructing a computational model for predicting stroke or a system or device embedded with the computational model, wherein the metabolites are selected from one or more of C14.0, C15.0, C20.0, and C18.3N6.
[0009] The present invention provides a readable storage medium on which is stored a metabolite-based computational model for predicting stroke, wherein the metabolites are selected from one or more of C14.0, C15.0, C20.0, and C18.3N6.
[0010] The present invention provides a calculation model of stroke or a system or device embedded with the calculation model, wherein the calculation model obtains one or more levels of C14.0, C15.0, C20.0, and C18.3N6, and outputs a discriminant value to determine the risk of stroke.
[0011] Advantages and beneficial effects of the present invention:
[0012] The present invention discovered for the first time the biomarkers associated with stroke: C14.0, C15.0, C20.0, and C18.3N6. By detecting the levels of the biomarkers and comparing them with healthy controls, it is possible to determine whether the subject has a stroke and the risk of developing a stroke, in order to achieve early diagnosis of stroke, thereby performing early intervention treatment for stroke and improving the patient's quality of life and survival. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 It is the ROC curve of the model constructed by the random forest method of the training set;
[0014] Figure 2 This is the ROC curve of the model constructed by the random forest method of the test set;
[0015] Figure 3 This is the prediction confusion matrix result diagram of the training set using repeated 10-fold cross validation;
[0016] Figure 4 This is the prediction confusion matrix result graph of the test set using repeated 10-fold cross validation. DETAILED DESCRIPTION
[0017] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.
[0018] Unless otherwise indicated, the meaning of all terms (including technical and scientific terms) used to disclose the present invention is the same as that commonly understood by those of ordinary skill in the art to which the present invention belongs. By way of further guidance, the following definitions are used to better understand the teachings of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0019] As used herein, the terms "comprising", "including" and "comprising" are synonymous and are inclusive or open-ended and do not exclude additional, unrecited members, elements or method steps.
[0020] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0021] The present invention has been completed through extensive and in-depth research, by conducting metabolomics research on blood samples of stroke patients and healthy controls, screening metabolites showing significant differences, and further determining metabolites or metabolite combinations that can achieve accurate diagnosis of stroke through bioinformatics analysis.
[0022] The present invention provides biomarkers that can be used for stroke diagnosis. The biomarkers include metabolites, and the metabolites include C14.0, C15.0, C20.0, and C18.3N6.
[0023] In the present invention, biomarkers are differentially present at a level with statistical significance (ie, p-value less than 0.05 and / or q-value less than 0.10, as determined using Welch's T-test or Wilcoxon's rank-sum Test).
[0024] The present invention provides the use of a reagent for detecting a biomarker in a sample in the preparation of a product for diagnosing stroke, wherein the biomarker is selected from one or more of C14.0, C15.0, C20.0, and C18.3N6.
[0025] In one embodiment, stroke is diagnosed by detecting the level of metabolite C14.0.
[0026] In one embodiment, stroke is diagnosed by detecting the level of metabolite C15.0.
[0027] In one embodiment, stroke is diagnosed by detecting the level of metabolite C20.0.
[0028] In one embodiment, stroke is diagnosed by detecting the level of metabolite C18.3N6.
[0029] In some embodiments, stroke is diagnosed by detecting the levels of any two of the metabolites C14.0, C15.0, C20.0, and C18.3N6.
[0030] In some embodiments, stroke is diagnosed by detecting the levels of any three of the metabolites C14.0, C15.0, C20.0, and C18.3N6.
[0031] In a preferred embodiment, stroke is diagnosed by detecting the levels of C14.0, C15.0, C20.0, and C18.3N6.
[0032] In one embodiment, the stroke is an ischemic stroke, including but not limited to strokes classified as large artery atherosclerosis, cardioembolism, arteriolar occlusion, other causes or unknown causes according to the TOAST classification. Other causes refer to causes other than large artery atherosclerosis, cardioembolism and arteriolar occlusion, such as blood system diseases and vascular malformations.
[0033] In a specific embodiment, the stroke is a stroke of large artery atherosclerosis type according to TOAST classification.
[0034] In some embodiments, the reagent for detecting biomarkers in a sample can be any reagent used in any conventional detection method, including but not limited to chromatography, spectroscopy, mass spectrometry, nuclear magnetic resonance, and chemical analysis.
[0035] In one embodiment, the mass spectrometry is chromatography-mass spectrometry.
[0036] As an alternative embodiment, the chromatographic technique is gas chromatography, a combined technique known as gas chromatography-mass spectrometry (GC / MS, GCMS or GC-MS). As known to those skilled in the art, in this technique, a gas chromatograph is used to separate different compounds. The separated compound stream is fed to a mass spectrometer for ionization, mass analysis and detection as described above.
[0037] As another preferred embodiment, chromatographic technique is liquid chromatography, and the combined technique is called liquid chromatography-mass spectrometry (LC / MS, LCMS or LC-MS). As known to those skilled in the art, this technology uses liquid mobile phase chromatographic separation of compounds. Usually, the liquid phase is a mixture of water and an organic solvent. The separated compound stream is then fed into a mass spectrometer for ionization, mass analysis and detection as described above.
[0038] As a preferred embodiment, the mass spectrometry is tandem mass spectrometry. The tandem mass spectrometry is selected from ion trap mass spectrometry, quadrupole time-of-flight mass spectrometry, triple quadrupole mass spectrometry, quadrupole ion trap mass spectrometry, ion mobility-quadrupole ion trap-time-of-flight mass spectrometry, quadrupole-orbitrap mass spectrometry, ion mobility spectrometer-quadrupole ion trap mass spectrometry, triple quadrupole-orbitrap mass spectrometry, quadrupole ion trap-orbitrap mass spectrometry, time-of-flight or ion trap-Fourier transform mass spectrometry.
[0039] "Sample" and "specimen" are used interchangeably in the present invention and refer to a composition obtained or derived from a subject (e.g., an individual of interest) that contains cells and / or other molecular entities to be characterized and / or identified based on, for example, physical, biochemical, chemical and / or physiological characteristics. For example, the phrase "disease sample" or variations thereof refers to any sample obtained from a subject of interest that is expected or known to contain cells and / or molecular entities to be characterized. Samples include, but are not limited to, tissue samples (e.g., tumor tissue samples), primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous humor, lymphatic fluid, synovial fluid, follicular fluid, semen, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tumor lysates, and tissue culture medium, tissue extracts such as homogenized tissue, tumor tissue, cell extracts, and combinations thereof.
[0040] In some embodiments, the sample is selected from blood, serum, and plasma.
[0041] In a specific embodiment, said sample is selected from plasma.
[0042] After separation and analysis by appropriate mass spectrometry, the metabolites identified in the subject's sample can be used to detect stroke in the subject. Typically, this step includes comparing the level of the biomarker in the subject's sample with a reference value, wherein the level of the biomarker in the sample compared to the reference value indicates a stroke in the subject.
[0043] As an optional embodiment, a decrease in the level of a biomarker in the sample compared to the reference value indicates a stroke in the subject. In one embodiment, an increase in the level of a metabolite in the sample compared to the reference value indicates a stroke in the subject. The difference compared to the reference value can be an increase as defined and exemplified below, or a decrease as defined and exemplified below.
[0044] Typically, an increase or decrease in the level of a biomarker in a sample compared to a reference value is measured as a % mean difference. In this specification, the term "% mean difference" refers to the % difference in total ion counts for each mass ion in subjects with stroke compared to the total ion counts in a reference subject (i.e., control).
[0045] In cases where the measured values included an increase in the total ion counts of the appropriate mass ions in subjects with stroke, the % mean difference was measured as (mean disease / mean control) x 100% compared to the reference value. In cases where the measured values included a decrease in the total ion counts of the appropriate mass ions in subjects with disease, the % mean difference was measured as (mean control / mean disease) x 100% compared to the reference value. Therefore, the % mean difference always exceeded 100%, except in cases where the total ion counts of the appropriate mass ions in subjects with stroke were exactly the same as the reference value.
[0046] In embodiments where an increase in the level of a biomarker in a sample compared to a reference value is indicative of a stroke in a subject, the % mean difference in the level of one or more biomarkers in the sample compared to the reference value is not particularly limited.In one embodiment, the % average difference is at least 100%, such as at least 101%, such as at least 102%, such as at least 103%, such as at least 104%, such as at least 105%, such as at least 106%, such as at least 107%, such as at least 108%, such as at least 109%, such as at least 110%, such as at least 112%, such as at least 114%, such as at least 116%, such as at least 118%, such as at least 120%, such as at least 130%, such as at least 140%, such as at least 150%, such as at least 160%, such as at least 170%, such as at least 180%, such as at least 190%, such as at least 200%, such as at least 250%, 0%, for example at least 300%, for example at least 350%, for example at least 400%, for example at least 450%, for example at least 500%, for example at least 550%, for example at least 600%, for example at least 650%, for example at least 700%, for example at least 750%, for example at least 800%, for example at least 850%, for example at least 900%, for example at least 950%, for example at least 1000%, for example at least 1100%, for example at least 1200%, for example at least 1300%, for example at least 1400%, for example at least 1500%, for example at least 1600%, for example at least 1700%, for example at least 1800%, for example at least 1900%, for example at least 2000% , for example at least 2500%, for example at least 3000%, for example at least 3500%, for example at least 4000%, for example at least 4500%, for example at least 5000%, for example at least 5500%, for example at least 6000%, for example at least 6500%, for example at least 7000%, for example at least 7500%, for example at least 8000%, for example at least 8500%, for example at least 9000%, for example at least 9500%, for example at least 10,000%, for example at least 11,000%, for example at least 12,000%, for example at least 13,000%, for example at least 14,000%, for example at least 15,000%, for example at least 16,000%, for example at least At least 17,000%, for example at least 18,000%, for example at least 19,000%, for example at least 20,000%, for example at least 25,000%, for example at least 30,000%, for example at least 35,000%, for example at least 40,000%, for example at least 45,000%, for example at least 50,000%, for example at least 55,000%, for example at least 60,000%, for example at least 65,000%, for example at least 70,000%, for example at least 75,000%, for example at least 80,000%, for example at least 85,000%, for example at least 90,000%, for example at least 95,000%, for example at least 100,000%.
[0047] In embodiments where an increase in the level of a biomarker in a sample compared to a reference value is indicative of a stroke in a subject, the % mean difference is typically 101% to 15,000%, such as 105% to 12,000%, such as 110% to 10,000%, such as 110% to 9000%, such as 120% to 8000%, such as 130% to 7000%, such as 140% to 6000%, such as 150% to 5000%, such as 160% to 4000%, such as 170% to 3000%, such as 180% to 2500%, such as 190% to 2250%, such as 200% to 2000%, such as 250% to 1900%, such as 300% to 1800%, such as 350% to 1700%, such as 400% to 1600%, such as 450% to 1550%, such as 500% to 1500%.
[0048] In embodiments where a decrease in the level of a biomarker in a sample compared to a reference value indicates a stroke in a subject, the % mean difference in the level of the biomarker in the sample compared to the reference value is not particularly limited.In one embodiment, the % average difference is at least 100%, such as at least 101%, such as at least 102%, such as at least 103%, such as at least 104%, such as at least 105%, such as at least 106%, such as at least 107%, such as at least 108%, such as at least 109%, such as at least 110%, such as at least 112%, such as at least 114%, such as at least 116%, such as at least 118%, such as at least 120%, such as at least 130%, such as at least 140%, such as at least 150%, such as at least 160%, such as at least 170%, such as at least 180%, such as at least 190%, such as at least 200%, such as at least 250%, 0%, for example at least 300%, for example at least 350%, for example at least 400%, for example at least 450%, for example at least 500%, for example at least 550%, for example at least 600%, for example at least 650%, for example at least 700%, for example at least 750%, for example at least 800%, for example at least 850%, for example at least 900%, for example at least 950%, for example at least 1000%, for example at least 1100%, for example at least 1200%, for example at least 1300%, for example at least 1400%, for example at least 1500%, for example at least 1600%, for example at least 1700%, for example at least 1800%, for example at least 1900%, for example at least 2000% , for example at least 2500%, for example at least 3000%, for example at least 3500%, for example at least 4000%, for example at least 4500%, for example at least 5000%, for example at least 5500%, for example at least 6000%, for example at least 6500%, for example at least 7000%, for example at least 7500%, for example at least 8000%, for example at least 8500%, for example at least 9000%, for example at least 9500%, for example at least 10,000%, for example at least 11,000%, for example at least 12,000%, for example at least 13,000%, for example at least 14,000%, for example at least 15,000%, for example at least 16,000%, for example at least At least 17,000%, for example at least 18,000%, for example at least 19,000%, for example at least 20,000%, for example at least 25,000%, for example at least 30,000%, for example at least 35,000%, for example at least 40,000%, for example at least 45,000%, for example at least 50,000%, for example at least 55,000%, for example at least 60,000%, for example at least 65,000%, for example at least 70,000%, for example at least 75,000%, for example at least 80,000%, for example at least 85,000%, for example at least 90,000%, for example at least 95,000%, for example at least 100,000%.
[0049] The present invention provides a kit for diagnosing stroke, the kit comprising a reagent for detecting metabolites in a sample; and instructions for using the kit to evaluate whether a subject has or is susceptible to stroke, wherein the metabolites are selected from one or more of the following: C14.0, C15.0, C20.0, C18.3N6.
[0050] In some embodiments, the reagent detects the content and / or concentration of C14.0, C15.0, C20.0, and C18.3N6.
[0051] Furthermore, the kit also includes reagents for processing samples.
[0052] The most reliable results may be obtained when the sample is processed in a laboratory environment. For example, a sample may be obtained from a subject in a doctor's office and then sent to a hospital or commercial medical laboratory for further testing. However, in many cases, it may be desirable to provide instant results in a clinician's office or allow a subject to perform the test at home. In some cases, the need for a portable, prepackaged, disposable test that can be used by a subject without assistance or guidance, etc., is more important than a high degree of accuracy. In many cases, especially in the case of a physician follow-up, a preliminary test, even a test with reduced sensitivity and / or specificity, may be sufficient. Therefore, an assay provided in the form of a kit may involve detecting and measuring a relatively small amount of metabolites to reduce the complexity and cost of the assay.
[0053] Any form of sample assay capable of detecting sample metabolites as described herein can be used. Typically, the assay will quantify metabolites in the sample to a certain extent, such as whether their concentration or amount is above or below a predetermined threshold. Such kits can take the form of test strips, dip rods, boxes, cartridges, chip-based or bead-based arrays, multi-well plates, or a series of containers, etc. One or more reagents are provided to detect the presence and / or concentration and / or amount of selected sample metabolites. The sample of the subject can be directly assigned to the assay, or indirectly assigned to the assay from a stored or previously obtained sample. The presence or absence of metabolites above or below a predetermined threshold can be displayed, for example, by chromogenic, fluorescing, electrochemiluminescence, or other outputs (e.g., as in enzyme immunoassays (EIA), such as enzyme-linked immunosorbent assays (ELISA)).
[0054] In one embodiment, the test kit may include a solid substrate such as a chip, a slide, an array, etc., which has a reagent capable of detecting and / or quantitatively fixing one or more sample metabolites at a predetermined position on the substrate. As an illustrative example, a reagent fixed at a discrete predetermined position may be provided to the chip for detecting and quantifying the presence and / or concentration and / or amount of biomarkers in a sample. As described above, the level of the biomarker is found to be reduced in a sample of a subject suffering from a stroke. The chip may be configured so that a detectable output (such as a color change) is provided only when the concentration of one or more of these metabolites exceeds a threshold value, and the threshold value is selected or distinguished to indicate the concentration and / or amount of the biomarker of the control subject and the concentration and / or amount of the biomarker of the patient suffering from or susceptible to a stroke. Therefore, the presence of a detectable output (such as a color change) immediately indicates that a significantly reduced level of biomarkers is included in the sample, indicating that the subject suffers from or is susceptible to a stroke.
[0055] The present invention provides the use of metabolites in constructing a computational model for predicting stroke or a system or device embedded with the computational model, wherein the metabolites are selected from one or more of C14.0, C15.0, C20.0, and C18.3N6.
[0056] The computational model adopts an algorithm developed and obtained by applying statistical methods. For example, suitable statistical methods are discriminant analysis (DA) (i.e., linear, quadratic, regular DA), Kernel methods (i.e., SVM), nonparametric methods (i.e., k- nearest neighbor classifiers), PLS (partial least squares), tree-based methods (i.e., logistic regression, CART, random forest methods, boosting / bagging methods), generalized linear models (i.e., logarithmic regression), principal component-based methods (i.e., SIMCA), generalized superposition models, methods based on fuzzy logic, methods based on neural networks and genetic algorithms. Skilled technicians will not have problems selecting suitable statistical methods to evaluate the marker combination of the present invention and thus obtain suitable mathematical algorithms. In one embodiment, the statistical method for obtaining the mathematical algorithm used in the assessment of stroke is selected from DA (i.e., linear, quadratic, regular discriminant analysis), Kernel methods (i.e., SVM), nonparametric methods (i.e., k- nearest neighbor classifiers), PLS (partial least squares), tree-based methods (i.e., logistic regression, CART, random forest methods, boosting methods), or generalized linear models (i.e., logarithmic regression).
[0057] The area under the receiver operating curve (=AUC) is an indicator of the performance or accuracy of a diagnostic procedure. The accuracy of a diagnostic method is best described by its receiver operating characteristic (ROC). The ROC plot is a line graph of all sensitivity / specificity pairs resulting from continuously varying the decision threshold over the entire range of data observed.
[0058] On the x-axis is the false positive fraction, or 1-specificity [defined as (number of false positive results) / (number of true negatives + number of false positive results)]. It is a measure of specificity and is calculated entirely from unaffected subgroups. Because the true and false positive fractions are calculated completely separately using test results from two different subgroups, the ROC plot is independent of the prevalence of the disease in the sample. Each point on the ROC plot represents a sensitivity / 1-specificity corresponding to a particular decision threshold. A test with perfect discrimination (no overlap in the two result distributions) has an ROC plot through the upper left corner, where the true positive fraction is 1.0, or 100% (perfect sensitivity) and the false positive fraction is 0 (perfect specificity). The theoretical plot for a test that does not discriminate (the two groups have identical result distributions) is a 45° diagonal line from the lower left corner to the upper right corner. Most plots fall between these two extremes. (If the ROC plot falls completely below the 45° diagonal, this is easily corrected by reversing the criteria for "positive" from "greater than" to "less than" or vice versa.) Qualitatively, the closer the plot is to the upper left corner, the higher the overall accuracy of the test.
[0059] The overall assay sensitivity will depend on the specificity required to implement the methods disclosed herein. In certain preferred arrangements, a specificity of 75% may be sufficient, and statistical methods and resulting algorithms may be based on this specificity requirement. In a preferred embodiment, the method for assessing an individual at risk of stroke is based on a specificity of 80%, 85%, or also preferably 90% or 95%.
[0060] In one embodiment, the computational model is constructed using a random forest method.
[0061] The present invention provides a readable storage medium on which is stored a metabolite-based computational model for predicting stroke, wherein the metabolites are selected from one or more of C14.0, C15.0, C20.0, and C18.3N6.
[0062] In one embodiment, the computational model is constructed using a random forest method.
[0063] The present invention provides a calculation model of stroke or a system or device embedded with the calculation model, wherein the calculation model obtains one or more levels of C14.0, C15.0, C20.0, and C18.3N6 and outputs a discriminant value.
[0064] In a preferred embodiment, the calculation model obtains the level output discrimination values of C14.0, C15.0, C20.0 and C18.3N6.
[0065] The discriminant value is calculated based on the concentration and / or amount of the biomarker in the sample and the discriminant having the concentration and / or amount of the biomarker as an explanatory variable stored in a computational model.
[0066] The present invention provides the use of a biomarker in preparing a drug for treating stroke, wherein the biomarker is selected from one or more of C14.0, C15.0, C20.0, and C18.3N6.
[0067] The present invention will be further described in detail below in conjunction with the accompanying drawings and examples. The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for which specific conditions are not specified in the examples are usually based on conventional conditions.
[0068] Example Screening and efficacy determination of stroke-related metabolites
[0069] 1. Sample collection
[0070] Blood samples from 55 patients with ischemic stroke (AIS) and 63 controls were collected; they were divided into training set and test set. The training set included 45 healthy controls and 39 patients with ischemic stroke; the test set included 18 healthy controls and 16 patients with ischemic stroke. All samples were obtained with informed consent from patients and their families. Inclusion criteria are as follows:
[0071] Inclusion criteria
[0072] Stroke group:
[0073] 1) Aged 18-80 years old; 2) Patients diagnosed with large artery atherosclerosis according to TOAST classification for the first onset of the disease; 3) Within 14 days of onset; 4) ≤ 3 risk factors for the disease, including previous hypertension, diabetes, hyperlipidemia, stroke, and coronary heart disease.
[0074] Control group:
[0075] 1) All blood biochemical indicators are normal; 2) Age 18-80 years old.
[0076] Exclusion criteria
[0077] Stroke group:
[0078] 1) Patients with hemorrhagic stroke and mixed stroke as the first onset, as well as transient ischemic attack or hemorrhagic cerebrovascular disease; 2) Intracranial tumors and tumor stroke; 3) Intracranial infectious diseases; 4) Neurological deficits caused by non-neurovascular reasons such as malignant tumors, severe lung infections, severe heart, liver and kidney dysfunction and hemorrhagic diseases; 5) Patients with severe mental illness; 6) Patients with ischemic stroke after carotid artery stenting or angioplasty were excluded; 7) Pregnant and lactating women; 8) Incomplete clinical data.
[0079] Control group:
[0080] 1) Obvious neurological impairment due to cerebrovascular or other causes; 2) Neurological impairment caused by non-neurovascular causes such as malignant tumors, severe lung infections, severe heart, liver and kidney dysfunction and hemorrhagic diseases; 3) Patients with severe mental illness; 4) Pregnant and lactating women; 5) Incomplete clinical data.
[0081] 2. Metabolomics testing
[0082] 1) Pre-processing
[0083] Standard product configuration
[0084] 51 kinds of fatty acid methyl ester mixed standard solutions (4000μg / mL) were prepared with n-hexane into 1μg / mL, 5μg / mL, 10μg / mL, 25μg / mL, 50μg / mL, 100μg / mL, 250μg / mL, 500μg / mL, 1000μg / mL, 2000μg / mL ten mixed standard concentration gradients, where the concentration is the total concentration of each component. The mother solution was stored at -20℃, and the working standard solution was prepared and used immediately.
[0085] Metabolite extraction
[0086] Accurately pipette an appropriate amount of sample into a 10mL glass centrifuge tube, add 2mL of 1% sulfuric acid methanol solution, and mix thoroughly; esterify in a 80℃ water bath for 30min; take out and cool, accurately add 1mL of n-hexane for extraction, shake and mix, let stand for 2min, then add 5mL of H2O (4℃) for washing, and centrifuge at 3500rpm for 10min at 4℃; accurately pipette 700μL of supernatant into a 2mL centrifuge tube, add 100mg of anhydrous sodium sulfate powder to remove excess water, and shake to mix; accurately pipette 300μL of supernatant into a 2mL centrifuge tube, add 15μL of 500ppm methyl salicylate as an internal standard, shake and mix, and pipette an appropriate amount of supernatant into the detection bottle.
[0087] 2) On-machine testing
[0088] Thermo gas chromatograph (model TRACE 1300) and mass spectrometer (ISQ 7000) were used for detection.
[0089] Chromatographic conditions
[0090] Thermo Trace 1300 (Thermo Fisher Scientific, USA) gas phase system, chromatographic column ThermoTG-FAME capillary column (50m*0.25mm ID*0.20μm); split injection, injection volume 1μL, split ratio 8:1. Injection port temperature 250℃; ion source temperature 300℃; transfer line temperature 280℃. The program temperature was 80℃ starting temperature, maintained for 1min; increased to 60℃ at 20℃ / min, maintained for 1.5min; increased to 196℃ at 3℃ / min, maintained for 8.5min; finally increased to 250℃ at 20℃ / min, maintained for 3min. The carrier gas was helium, and the carrier gas flow rate was 0.63mL / min.
[0091] Mass spectrometry conditions
[0092] Thermo ISQ 7000 mass spectrometer (Thermo Fisher Scientific, USA) was used with electron impact ionization (EI) source, SIM scanning mode, and electron energy of 70 eV.
[0093] 3. Data Analysis
[0094] Data preprocessing:
[0095] The metabolomics was standardized using autoscaling (mean-centering and scaled to unit variance, UV).
[0096] Screening of differential metabolites and analysis of diagnostic efficacy
[0097] The mean and standard deviation of each group were calculated for the standardized data, and then the statistically significant pvalue and fold change value were calculated to screen metabolites showing significant differences (P<0.05).
[0098] Model construction:
[0099] Through metabolomics data preprocessing, Normalization and missing value filling, low-variance features were deleted to remove features with small changes, and features highly correlated with other features were deleted. The data were standardized and missing values were filled. Recursive feature elimination (RFE) was used to preliminarily screen feature variables to build the model. When building the model, the randomForest package in R language was used for training. Repeated 10-fold cross validation was used to evaluate the model performance during the training process. The model was optimized by screening out the best feature subset.
[0100] The random forest model was constructed using the screened characteristic metabolite data, and the leave-one-out cross-validation method was used to obtain the model's prediction results.
[0101] 4. Results
[0102] The results of bioinformatics analysis showed that compared with the control group, C14.0, C15.0, C20.0, and C18.3N6 showed significant differences in the stroke group.
[0103] The ROC curve of the model constructed using the training set and the test set is as follows Figure 1 and Figure 2 As shown in the figure, the AUC values of the two models for stroke diagnosis were 0.807 and 0.819, respectively.
[0104] During the model construction process, the four characteristic metabolites and their model coefficients are:
[0105]
[0106] The prediction confusion matrix results of the training set and test set using repeated 10-fold cross validation are as follows Figure 3 and Figure 4 As shown, the model containing the above four features built using random forest has good sensitivity and specificity.
[0107] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. Use of a reagent for detecting biomarkers in a sample in the preparation of a product for diagnosing stroke, characterized in that: The biomarker is selected from one or more of C14.0, C15.0, C20.0, and C18.3N6.
2. The use according to claim 1, characterized in that: The biomarkers are selected from C14.0, C15.0, C20.0, and C18.3N6.
3. The application according to claim 1, characterized in that: The reagents include reagents for chromatography, spectroscopy, mass spectrometry, nuclear magnetic resonance, and chemical analysis; Preferably, the mass spectrometry is chromatography-mass spectrometry; Preferably, the mass spectrometry is tandem mass spectrometry.
4. The use according to any one of claims 1 to 3, characterized in that: The sample is selected from the group consisting of blood, serum, and plasma.
5. The use according to any one of claims 1 to 3, characterized in that: The stroke is an ischemic stroke; Preferably, the stroke is acute ischemic stroke.
6. A kit for diagnosing stroke, characterized in that: The kit comprises reagents for detecting metabolites in a sample; and instructions for using the kit to assess whether a subject has or is susceptible to stroke; the metabolites are selected from one or more of the following: C14.0, C15.0, C20.0, C18.3N6.
7. The kit according to claim 6, characterized in that The kit also includes reagents for processing the sample.
8. Application of metabolites in constructing a computational model for predicting stroke or in a system or device embedded with the computational model, characterized in that the metabolites are selected from one or more of C14.0, C15.0, C20.0, and C18.3N6.
9. A readable storage medium, characterized in that: A metabolite-based computational model for predicting stroke is stored thereon, wherein the metabolite is selected from one or more of C14.0, C15.0, C20.0, and C18.3N6; Preferably, the metabolite is selected from C14.0, C15.0, C20.0 and C18.3N6; Preferably, the computational model is constructed using a random forest method.
10. A computational model of stroke or a system or device embedded with the computational model, characterized in that: The calculation model obtains one or more levels of C14.0, C15.0, C20.0, and C18.3N6, and outputs a discriminant value to determine the risk of stroke; Preferably, the computational model is constructed using a random forest method.
Citation Information
Cited By
Cerebral arterial thrombosis risk assessment model fusing environmental exposure omics and metabolome biomarkers and model construction method
CN122050846A
An ischemic stroke risk assessment model fusing environmental exposomics and metabolomics biomarkers and a model construction method
CN122050846B
